AlzeCure is sponsored by           

AlzeCure presents major progress at International Alzheimer Conference

Press Release 12 September 2016

AlzeCure to present data from its TrkA and TrkB positive allosteric modulator program for Alzheimer’s disease at the 17th International Conference on Alzheimer’s Drug Discovery

Stockholm, Sweden, 12th September 2016 - AlzeCure announces that data from its TrkA and TrkB positive allosteric modulator program for Alzheimer’s disease will be presented at the 17th International Conference on Alzheimer’s Drug Discovery in Jersey City, NJ, USA. The oral presentation will include preclinical in vivo Proof-of-Principle data of AC-1122, an approved drug that is undergoing repurposing for the treatment of Alzheimer’s disease. The data to be presented support the use of positive allosteric modulators (PAMs) of Trk A and Trk B, enhancing the effects of the endogenous neuronal growth factors NGF and BDNF, for the treatment of Alzheimer’s disease:

• AC-1122 and PAMs from two back-up series reversed memory impairment caused by both cholinergic and glutamatergic deficits in an in vivo animal model at clinically relevant exposure.

• Based upon existing literature and previous clinical trials, we anticipate that the final drug will be a disease modifier with potent cognition enhancing effects.

”We are very excited about these promising data. The program comprises a high degree of innovation in combination with well-validated pathways for neuroprotection and neurorestoration genetically linked to Alzheimer’s disease. We have identified an approved medicine (AC-1122), which show potent cognitive enhancing effects in vivo. Our plan is to repurpose this drug for the treatment of Alzheimer’s disease and to pursue two promising lead optimization-series into preclinical development. By using pre-existing toxicology and safety pharmacology data for AC-1122, both costs and risks are kept at a low level”, said Jonas Ekstrand, PhD, CEO of AlzeCure Foundation.

Data to be presented at the 17th International Conference on Alzheimer’s Drug Discovery include:

Oral presentation: Session II, Novel Strategies for Neuroprotection, Monday September 12, 1:40-2:00, NeuroRestore - Development of Positive Allosteric Modulators of TrkA and TrkB. Dr. Pontus Forsell, CSO. For more information please visit www.alzdiscovery.org/events/event/17th-international-conference-on-alzheimers-drug-discovery

Alzheimer’s disease: The total number of people with dementia worldwide is estimated at more than 45 million and is projected to nearly double every 20 years. Being the most common form of dementia, Alzheimer's Disease (AD) accounts for 60-70% of all dementia cases. Given that there is currently no treatment on the market that can cure or even alter the progressive course of AD, the unmet medical need is huge. A successful disease modifying treatment would therefore have a very large potential value.

AlzeCure’s positive allosteric modulators (PAMs):

The drug discovery program is composed of one lead candidate drug and two back-up series of drug-like molecules. Their primary mechanism of action is to enhance the effect of two important neuronal growth factors, NGF and BDNF, by acting as positive allosteric modulators of the receptors TrkA and TrkB. NGF and BDNF both play pivotal and complimentary roles in neurorestoration as well as in synaptic plasticity and cognitive function. Interestingly, BDNF is today the only genetic factor known to moderate downstream effects of amyloid-beta induced neurotoxicity, suggesting that methods to increase BDNF signaling are a unique and viable therapeutic alternative for the treatment of Alzheimer’s disease. It is also envisioned that such a treatment would be an excellent complement to the many different anti-amyloid and tau strategies that are currently in clinical development.

About AlzeCure:

AlzeCure Foundation is a Swedish research organization located at Karolinska Institutet Science Park in Stockholm and focused on the development of novel therapeutics and diagnostics for Alzheimer’s disease and other neurodegenerative disorders. With the support of Alzheimerfonden (the Swedish Alzheimer's foundation) and in cooperation with Professor Bengt Winblad of Karolinska Institutet, AlzeCure was founded in 2012 by a group of pharma industry professionals with extensive experience of drug discovery and research within neuroscience. AlzeCure’s unique business model is based on a scientific network that consists of the world's leading experts in neurodegenerative diseases, both in preclinical and clinical research. Our collaborators are closely linked to AlzeCure, combining disease knowledge, unique ideas, state-of-the-art technology and industrial stringency. Funding for the TrkA and TrkB positive allosteric modulator program is provided for by the Alzheimer’s Drug Discovery Foundation. The ADDF catalyzes and funds drug discovery and drug development for Alzheimer's disease and related disorders. To learn more about the ADDF, visit the website at: www.alzdiscovery.org.

Contact:

Jonas Ekstrand, PhD

CEO AlzeCure Foundation

Tel. +46 70 302 08 96

This email address is being protected from spambots. You need JavaScript enabled to view it.

see full press release here